26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies

Acute Suicide Risk Stratification & Clinical Evaluation

Suicide represents a leading cause of preventable mortality worldwide, accounting for nearly 50,000 deaths annually in the United States alone. Primary care and urgent care clinicians occupy a critical diagnostic frontline: studies demonstrate that approximately 45% of individuals who die by suicide visit a primary care physician in the month preceding their death, and up to 20% do so in the preceding 24 to 48 hours. Rapid, systematic risk stratification, decisive environmental control, and lethal means restriction are vital, life-saving clinical competencies tested rigorously on the ABFM certification examination.

Static versus Dynamic Risk Factors

Clinical risk stratification begins by distinguishing immutable demographic and historical vulnerabilities from modifiable, acute precipitants:

• Static (Fixed) Risk Factors:
  • Prior Suicide Attempt: The single most powerful clinical predictor of future completed suicide. Patients with a prior attempt carry a 30- to 40-fold higher lifetime risk compared to the general population.
  • Demographics: Male sex (men complete suicide at nearly 4 times the rate of women, primarily due to higher-lethality methods such as firearms; women exhibit higher rates of suicide attempts); older age (men aged ≥75 years exhibit the highest demographic suicide rate); sexual and gender minority status (LGBTQ+ youth experience elevated risk secondary to minority stress and social alienation).
  • Family History & Genetics: First-degree family history of completed suicide, familial mood disorders, and early childhood physical or sexual abuse.
  • Chronic Debilitating Medical Illness: Chronic intractable pain syndromes, terminal malignancies, neurodegenerative disorders (e.g., ALS, Huntington disease, Parkinson disease), and severe traumatic brain injury.
• Dynamic (Modifiable / Acute) Risk Factors:
  • Severe Psychic Anxiety, Agitation, and Insomnia: Acute severe psychic pain, akathisia, and intractable insomnia represent immediate short-term red flags for imminent suicidal behavior within 24 to 72 hours.
  • Substance Intoxication & Substance Use Disorders: Acute alcohol or illicit drug intoxication drastically lowers impulse control, impairs cognitive flexibility, and increases lethal behavioral action.
  • Acute Relational or Financial Crises: Sudden divorce, romantic rejection, arrest, bankruptcy, or acute bereavement.
  • Profound Hopelessness & Perceived Burdensomeness: The psychological conviction that one is a burden to loved ones and that future suffering is inescapable.
  • Active Psychotic Symptoms: Command auditory hallucinations instructing self-harm, or severe persecutory delusions where self-harm is perceived as the only escape.

Validated Risk Stratification Tools: C-SSRS and SAFE-T

Subjective clinical intuition alone is notoriously unreliable for predicting suicide. Guidelines from the American Academy of Family Physicians (AAFP) and The Joint Commission mandate the implementation of standardized, evidence-based screening instruments:

1. Columbia-Suicide Severity Rating Scale (C-SSRS): The C-SSRS systematically deconstructs suicidal thinking across a hierarchical 6-item progression, establishing clinical severity and immediate disposition:

   • Item 1 (Passive Ideation): Wish to be dead ("Have you wished you were dead or wished you could go to sleep and not wake up?").
   • Item 2 (Active Ideation): General non-specific suicidal thoughts ("Have you actually had any thoughts of killing yourself?").
   • Item 3 (Active Ideation with Method): Suicidal thoughts with potential methods without a specific plan ("Have you been thinking about how you might do this?").
   • Item 4 (Active Ideation with Intent): Suicidal thoughts with intent to act, but no specific plan ("Have you had these thoughts and had some intention of acting on them?").
   • Item 5 (Active Ideation with Specific Plan and Intent): Suicide thoughts with an explicit plan and intent ("Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?").
   • Item 6 (Preparatory Behavior): Engaging in preparatory acts (e.g., collecting pills, buying a firearm, writing a suicide note, giving away possessions, or rehearsing the act).

2. SAFE-T Framework (Suicide Assessment Five-Step Evaluation and Triage):

   • Step 1: Identify Risk Factors (prior attempts, mood disorders, substance abuse, acute stressors).
   • Step 2: Identify Protective Factors (internal: coping skills, religious/spiritual beliefs against suicide; external: responsibility to dependent children/pets, strong therapeutic rapport, robust social support).
   • Step 3: Conduct Specific Suicide Inquiry (explore ideation nature, frequency, duration, plan specificity, intent, lethality, and access to means).
   • Step 4: Determine Risk Level and Choose Intervention (High, Moderate, Low).
   • Step 5: Document Triage, Rationale, and Follow-Up Safety Plan.

Suicide Risk Stratification Matrix

---\n

Lethal Means Counseling & The Stanley-Brown Safety Plan

Lethal Means Counseling: The Core Life-Saving Intervention

Suicidal crises are characteristically acute, impulsive, and time-limited: empirical psychological autopsies demonstrate that the interval between the decision to act and the actual suicide attempt is frequently less than 10 to 60 minutes. If lethal means are readily accessible during this acute cognitive constriction, fatal outcomes surge dramatically. Conversely, restricting access to lethal means saves lives—individuals forced to delay an attempt or substitute less lethal methods rarely substitute equally lethal alternatives.

• Firearms: The paramount target of lethal means counseling. Firearms account for over 50% of all completed suicides in the United States, boasting a case fatality rate exceeding 85% to 90% (compared to <2% for drug overdoses). Family physicians must routinely and directly ask: "Are there any firearms or guns in your home or accessible to you?"
  • Intervention: Counsel that during times of emotional crisis, firearms must be removed from the home entirely (transferred to a licensed firearm dealer, secure storage facility, or trusted off-site relative outside the household, in accordance with state gun laws). If temporary off-site removal is refused, mandate that firearms be stored unloaded, locked in a secure gun safe or with cable locks, with ammunition locked in a separate container and keys/combinations entrusted to a third party.
• Medication Restriction: Remove large supplies of prescription and over-the-counter medications (e.g., acetaminophen, tricyclic antidepressants, opioids, sedative-hypnotics). Prescribe medications in limited 7-day supplies with blister packs, and entrust medication administration to a reliable family member.

The Stanley-Brown Safety Planning Intervention (SPI)

The Stanley-Brown Safety Plan is an evidence-based, collaborative clinical intervention that empowers patients during emergent suicidal crises. It consists of six hierarchical steps written in the patient's own words:

1. Step 1: Warning Signs: Personal idiosyncratic thoughts, images, moods, or behavioral changes that signal a developing crisis (e.g., "isolating in my bedroom," "drinking alcohol alone at night," "feeling like a total failure").
2. Step 2: Internal Coping Strategies: Actions the patient can take independently to distract themselves without contacting another person (e.g., "going for a brisk 20-minute run," "listening to instrumental music," "practicing 4-7-8 deep diaphragmatic breathing").
3. Step 3: People and Social Settings that Provide Distraction: Healthy social environments and trusted acquaintances who can provide distraction without discussing the crisis (e.g., "calling my sister to talk about her children," "going to a busy coffee shop or public library").
4. Step 4: People Whom I Can Ask for Help: Trusted family members or close friends who can be openly confided in during an acute crisis (names and direct phone numbers).
5. Step 5: Professionals and Agencies to Contact: Specific healthcare professionals, local emergency departments, urgent care crisis centers, and national crisis lines: The 988 Suicide & Crisis Lifeline (call or text 988; 24/7/365 free, confidential support) and the Crisis Text Line (text HOME to 741741).
6. Step 6: Making the Environment Safe: Concrete, verified steps to restrict lethal means (e.g., "my spouse has locked all firearms in the basement safe and holds the only key," "my mother dispenses my medications daily").

The Fallacy and Danger of 'No-Suicide Contracts'

• Clinical Contraindication: Formal medical guidelines (AAFP, American Psychiatric Association [APA]) explicitly condemn the use of 'no-suicide contracts' (agreements where a patient signs a paper promising not to harm themselves).
• Why Contracts Fail:
  1. Zero Empirical Efficacy: No clinical trial has ever demonstrated that no-suicide contracts reduce suicide attempts or completed suicides.
  2. False Sense of Security: Clinicians frequently experience an illusory sense of safety, leading to inappropriate discharge of high-risk patients.
  3. Coercive and Destructive: Contracts can feel coercive, alienating patients and discouraging them from honestly reporting returning suicidal impulses.
  4. Zero Legal Protection: A no-suicide contract carries zero legal weight in malpractice litigation and does not protect a physician against liability for failing to perform an adequate risk assessment.

Involuntary Psychiatric Hold & Emergency Custody Protocols

When a patient is determined to be at imminent risk of suicide or severe harm but refuses voluntary evaluation or attempts to leave the clinical facility, clinicians must execute an Emergency Involuntary Psychiatric Hold (e.g., '5150' in California, 'Baker Act' in Florida, or state-specific equivalents).

• Statutory Criteria: The clinician must establish that due to a suspected or diagnosed mental disorder, the patient presents an:
  1. Imminent Danger to Self (active suicidal intent or life-threatening self-harm);
  2. Imminent Danger to Others (active homicidal intent or violent assaultive threats);
  3. Grave Disability (inability to provide for basic survival needs: food, clothing, or shelter, placing life in immediate jeopardy).
• Facility Management While Awaiting Transport:
  • Place the patient under continuous 1:1 visual observation (unbroken direct line of sight within arm's length by trained staff).
  • Secure the physical environment: remove all ligature points, electrical cords, call bells, bed linens, sharp objects, heavy medical equipment, and plastic trash can liners.
  • Ensure secure transport via Emergency Medical Services (EMS) or law enforcement—never allow family members to transport an actively suicidal patient in a private vehicle.

---\n

Acute Agitation: De-Escalation & Emergency Pharmacotherapy

Acute psychomotor agitation is characterized by excessive motor activity, heightened autonomic arousal, severe psychic tension, and verbal or physical aggression. It represents an emergency that threatens the safety of the patient, medical staff, and other patients.

Project BETA Verbal De-Escalation Framework

The American Association for Emergency Psychiatry's Project BETA (Behavioral Emergencies Communication and Assessment) establishes non-coercive verbal de-escalation as the mandatory first-line intervention prior to any pharmacologic or physical restraint:

1. Maintain Safety & Space: Maintain at least two arm-lengths of distance between yourself and the patient. Never corner the patient, and never allow the patient to block your unobstructed exit route.
2. Non-Provocative Body Language: Keep hands visible and unclenched; maintain an open, relaxed posture at a 45-degree angle rather than squaring off face-to-face; avoid prolonged intense eye contact.
3. Establish Verbal Contact: Designate a single clinician as the primary communicator to avoid sensory overload.
4. Concise, Repetitive Language: Agitated brains exhibit impaired executive processing; speak in short, simple, concrete sentences using a calm, soothing, monotone voice.
5. Identify Wants and Feelings: Validate emotional distress ("I can see that you are extremely upset, and I want to help you feel safe here") without validating false delusions.
6. Listen Actively: Paraphrase the patient's words to demonstrate comprehension.
7. Agree or Agree to Disagree: Find common ground ("I agree that you shouldn't have had to wait so long to see a doctor").
8. Set Clear, Respectful Limits: Explicitly state behavioral expectations without being punitive ("I want to help you, but you cannot throw chairs or scream at the nurses").
9. Offer Choices and Optimism: Offer small, empowering choices (e.g., "Would you prefer to sit in the recliner or the bed?" "Can I get you a glass of water or a warm blanket?").
10. Offer Medication Collaboratively: Frame pharmacotherapy as an aid to alleviate overwhelming distress ("We have medication that can help calm this terrible anxiety and help you feel more in control; would you like to take a pill or a liquid?").

Pharmacologic De-Escalation: Oral vs. Parenteral Pathways

When verbal de-escalation proves insufficient and the patient poses an imminent physical threat to self or others, emergency pharmacotherapy is indicated. The clinical goal is rapid calming without inducing deep sedation or unresponsiveness.

                    ACUTE AGITATION PHARMACOTHERAPY ALGORITHM

                             Patient Agitated
                                    │
                                    ▼
                  Project BETA Verbal De-escalation First-Line
                                    │
          ┌─────────────────────────┴─────────────────────────┐
          ▼                                                   ▼
   Cooperative Patient                               Combative / Violent / Refusing Oral
   (Oral Formulation Preferred)                      (Parenteral IM Formulation)
          │                                                   │
          ▼                                                   ▼
  Oral Atypical Antipsychotic + Benzodiazepine        SELECT REGIMEN:
  • Olanzapine 5-10 mg ODT  OR                        1. "B52" Protocol (Classic Standard):
  • Risperidone 1-2 mg ODT  OR                           • Haloperidol 5 mg IM +
  • Lorazepam 1-2 mg PO                                  • Lorazepam 2 mg IM +
                                                         • Diphenhydramine 50 mg IM (Prevents EPS!)
                                                      2. Second-Generation Antipsychotic IM Monotherapy:
                                                         • Olanzapine 5-10 mg IM  OR
                                                         • Ziprasidone 10-20 mg IM
                                                      3. Severe Excited Delirium / Hyperactive State:
                                                         • Ketamine 4-5 mg/kg IM
                                                              │
                                                              ▼
                                              CRITICAL SAFETY CONTRAINDICATION:
                                              NEVER co-administer IM Olanzapine with
                                              parenteral Benzodiazepines (Fatal Arrest!)

The 'B52' Protocol & Extrapyramidal Prophylaxis

• Components: Haloperidol 5 mg IM + Lorazepam 2 mg IM + Diphenhydramine 50 mg IM (frequently drawn into a single syringe or injected simultaneously).
• Mechanism & Synergy:
  • Haloperidol (high-potency typical antipsychotic) provides rapid D2 receptor antagonism to control agitation, psychosis, and mania.
  • Lorazepam (intermediate-acting benzodiazepine) provides GABAA agonism, producing rapid sedation, anxiolysis, and blunting haloperidol's pro-arrhythmic potential.
  • Diphenhydramine (anticholinergic/antihistamine) is essential: it blocks striatal muscarinic receptors to counteract the acute dopamine-acetylcholine imbalance caused by high-potency haloperidol, preventing acute extrapyramidal symptoms (EPS), specifically acute dystonic reactions (e.g., torticollis, oculogyric crisis, laryngospasm, opisthotonos).

Atypical Antipsychotic IM Monotherapy & Fatal Drug-Drug Interaction

• Intramuscular Second-Generation Antipsychotics:
  • Olanzapine 5 to 10 mg IM (onset 15-30 minutes); or
  • Ziprasidone 10 to 20 mg IM (onset 15-30 minutes; max 40 mg/day).
• THE CRITICAL BLACK BOX CONTRAINDICATION:
  • NEVER CO-ADMINISTER INTRAMUSCULAR OLANZAPINE WITH PARENTERAL BENZODIAZEPINES (intramuscular or intravenous lorazepam, diazepam, midazolam).
  • Co-administration induces synergistic, catastrophic central nervous system depression, profound hypotension, respiratory arrest, and sudden cardiovascular collapse. Clinical practice guidelines require maintaining a minimum separation window of at least 1 to 2 hours between parenteral doses of olanzapine and benzodiazepines.

Ketamine for Excited Delirium & Extreme Combative Agitation

• In cases of profound, life-threatening hyperactive delirium with violent combative behavior (excited delirium syndrome / severe sympathomimetic toxicity where traditional neuroleptics are slow or ineffective), Ketamine is the agent of choice.
• Dosing: 4 to 5 mg/kg IM (or 1 to 2 mg/kg IV).
• Advantages: NMDA receptor antagonism achieves complete dissociative calming within 2 to 5 minutes, rapidly halting dangerous physical exertion, hyperthermia, and metabolic acidosis without compromising spontaneous respiratory drive.
• Precautions: Monitor airway closely; risk of emergence reactions, hypersalivation, and laryngospasm (rare).

---\n

Serotonin Syndrome vs. Neuroleptic Malignant Syndrome

Both Serotonin Syndrome (SS) and Neuroleptic Malignant Syndrome (NMS) represent life-threatening hyperthermic drug toxicities presenting with altered mental status and autonomic instability. Dissecting their distinct pathophysiologies, clinical presentations, and antidotes is an essential ABFM board skill.

Master Differential: SS versus NMS

Hunter Toxicity Criteria for Serotonin Syndrome

To establish a diagnosis of Serotonin Syndrome, the patient must have been exposed to a serotonergic agent within the past 5 weeks AND demonstrate at least one of the following:

1. Spontaneous clonus;
2. Inducible clonus PLUS either agitation or diaphoresis;
3. Ocular clonus PLUS either agitation or diaphoresis;
4. Tremor PLUS hyperreflexia;
5. Hypertonia PLUS temperature >38°C PLUS either ocular clonus or inducible clonus.

Critical Clinical Pearl: Clonus (spontaneous, inducible, or ocular) is the single most specific and sensitive clinical physical examination sign distinguishing Serotonin Syndrome from Neuroleptic Malignant Syndrome.